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Abstract
Background: With persistent inconsistencies in colorectal cancer (CRC) miRNAs expression data, it is crucial to shift
toward inclusion of a “pre-laboratory” integrated analysis to expedite effective precision medicine and translational
research. Aberrant expression of hsa-miRNA-195 (miR-195) which is distinguished as a clinically noteworthy miRNA
has previously been observed in multiple cancers, yet its role in CRC remains unclear.
Methods: In this study, we performed an integrated analysis of seven CRC miRNAs expression datasets. The
expression of miR-195 was validated in The Cancer Genome Atlas (TCGA) datasets, and an independent validation
sample cohort. Colon cancer cells were transfected with miR-195 mimic and inhibitor, after which cell proliferation,
colony formation, migration, invasion, and dual luciferase reporter were assayed. Xenograft mouse models were
used to determine the role of miR-195 in CRC tumorigenicity in vivo.
Results: Four downregulated miRNAs (hsa-let-7a, hsa-miR-125b, hsa-miR-145, and hsa-miR-195) were demonstrated to
be potentially useful diagnostic markers in the clinical setting. CRC patients with a decreased level of miR-195-5p in
tumor tissues had significantly shortened survival as revealed by the TCGA colon adenocarcinoma (COAD) dataset and
our CRC cohort. Overexpression of miR-195-5p in DLD1 and HCT116 cells repressed cell growth, colony formation,
invasion, and migration. Inhibition of miR-195-5p function contributed to aberrant cell proliferation, migration, invasion,
and epithelial mesenchymal transition (EMT). We identified miR-195-5p binding sites within the 3’-untranslated region
(3′-UTR) of the human yes-associated protein (YAP) mRNA. YAP1 expression was downregulated after miR-195-5p
treatment by qRT-PCR analysis and western blot.
Conclusions: Four downregulated miRNAs were shown to be prime candidates for a panel of biomarkers with sufficient
diagnostic accuracy for CRC in a clinical setting. Our integrated microRNA profiling approach identified miR-195-5p
independently associated with prognosis in CRC. Our results demonstrated that miR-195-5p was a potent suppressor of
YAP1, and miR-195-5p-mediated downregulation of YAP1 significantly reduced tumor development in a mouse CRC
xenograft model. In the clinic, miR-195-5p can serve as a prognostic marker to predict the outcome of the CRC patients.




Department of Oncology, Zhongnan Hospital of Wuhan University, Hubei
Key Laboratory of Tumor Biological Behaviors & Hubei Cancer Clinical Study
Center, 430071 Wuhan, People’s Republic of China
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Sun et al. Journal of Hematology & Oncology  (2017) 10:79 
DOI 10.1186/s13045-017-0445-8
Background
Colorectal cancer (CRC) has been the fourth leading cause
of cancer death worldwide for several decades [1]. The 5-
year survival rate for localized stage CRC is 90%, whereas
as CRC spreads to the regional lymph nodes or distant
parts of the body, the 5-year survival rate plunges from
71% to 13% in the United States [2]. These malignancies
are ascribed to accumulation of genetic alterations, includ-
ing dissemination of proto-oncogenes, losing or inactivat-
ing of tumor suppressor genes, and EMT, which
ultimately lead to tumor evolution and progression [3–7].
Using the miRNA expression profile, dysregulated
microRNAs (miRNA/miR) in CRC can be identified. Spe-
cific miRNAs have been suggested as biomarkers for CRC
pathogenesis, metastasis, recurrence, and as potential
therapeutic targets [8]. Previous research, by examining a
series of CRC microRNAs expression profile data, recom-
mended several deregulated miRNAs, but most failed to
identify efficient miRNA biomarkers. Furthermore, few
mechanistic studies address the question of how miRNA
drives the alterations of the hallmark CRC signaling path-
ways [9]. For a collective set of deregulated miRNAs, ex-
perimental validation is still lacking, and the potential
mRNA targets of these miRNAs and their regulatory
mechanisms remain unknown. The multicenter sequen-
cing of 1893 carcinoma/normal paired samples revealed
that miR-195-5p was a tumor-suppressing miRNA and
was downregulated in tumor tissues [10]. Since predicted
targets of miR-195-5p were enriched for the Hippo/YAP
signaling pathway, we hypothesize that miR-195-5p may
function by targeting the YAP1 mRNA. Recent studies
showed that YAP and its transcriptional coactivator with
PDZ-binding motif (TAZ) function as a nexus on the
crosstalk of multiple signaling pathways, and therefore
can be potential therapeutic targets as the chief down-
stream effectors of the Hippo pathway in a variety of can-
cers [11–15]. It was documented that YAP and TAZ
overexpression resulted in a trend of shorter survival time
by multivariate analysis in CRC [16]. However, there have
been few studies on miRNAs that regulate the oncogenic
alterations in the Hippo signaling pathway.
We performed an integrated analysis and identified
significantly disturbed miRNAs by using microRNA se-
quencing data in primary tumors and paired adjacent
normal tissue (PANT), both derived from the CRC pa-
tients. We further validated aberrant expression patterns
of these miRNAs in the TCGA-COAD dataset [17]. We
distinguished miR-195-5p as a clinically noteworthy
miRNA in CRC as found in lung cancer [18]. We con-
firmed that the miR-195-5p level was high in patients
with favorable survival in TCGA, and may play a critical
role in CRC tumorigenesis. Ectopic expression of miR-
195-5p could significantly reduce proliferation, migra-
tion, invasion, and EMT in two colon cancer cell lines,
DLD1 and HCT116. We showed for the first time that
the full-length 3′-UTR of the human YAP1 mRNA was
a direct target of miR-195-5p. These data offer a plaus-
ible mechanism accounting for the tumor-suppressing
function of miR-195-5p, further supporting the notion
that the miR-195-5p/YAP1/EMT axis can be the thera-
peutic focus for eliminating CRC tumorigenesis [19].
Methods
Search strategy and data collection, preprocessing, and
normalization
Public microarray repositories were curated to search
through the PubMed, GEO (accession numbers GSE33124,
GSE35982, GSE33122, GSE35834, GSE33125, GSE33123,
GSE68306, GSE35834, GSE41655, GSE41012, GSE73178,
GSE54632, GSE68377, GSE48267, GSE54088, GSE45349,
GSE38389, GSE28364, GSE7828, GSE35602, GSE10259
and GSE49246) and Array Express (accession numbers E-
MTAB-96, E-GEOD-35834, E-GEOD-28364 and E-MTAB-
2479) through September 2015 (the full-detailed search
strategy and search terms are shown in Additional file 1:
Table S1). The reference sections of the regained studies
were analyzed for additional pertinent papers. The checklist
and pipeline for properly organizing the integrated analysis
were decided as recommended by Ramasamy, via the
reporting guidelines of microarray meta-analysis [20]. Only
original experimental studies that screened for different
miRNAs between CRC and PANT in humans were the first
choice for inclusion. Additional criteria for selection dic-
tated that the included datasets should contain at least 30
samples of CRC and PANT correspondingly. Exclusion
criteria included: (1) repeated reports by the same institute,
hospital; (2) a non-expression gene chip; and (3) a non-
whole-genome chip. All datasets were normalized individu-
ally on the base-2 logarithm by Robust Multi-Array
Average (RMA) and Linear Models for Microarray
(LIMMA) package and annotated by converting different
probe IDs to gene IDs. All miRNA names were standard-
ized according to miRBase version 17 via miRBase Tracker
and consisted with TCGA for subsequent validation [21].
Any probe that did not map to a gene ID was removed as
viral miRNAs or non-miRNA probes.
Integrated analysis of miRNAs expression datasets
To identify differentially expressed (DE) miRNAs be-
tween CRC and PANT, we used MetaOmics software
(http://www.pitt.edu/~tsengweb/MetaOmicsHome.htm)
executed as a MetaDE package [22]. For integrated analysis,
the mean and standard deviation (SD) filter thresholds were
specified as 10%. Considering the different stringencies of
the methods, Fisher’s method was performed for statistical
analysis of significance: a modified t test and permutation
method were used to extrapolate the P values [23]. One-
sided tests were applied to classify the upregulated or
Sun et al. Journal of Hematology & Oncology  (2017) 10:79 Page 2 of 16
downregulated DE miRNAs. A P value less than 0.05 was
considered statistically significant for the DE miRNAs.
Integrated-signature miRNA analysis of TCGA
The results of integrated analysis of miRNAs expression
datasets were validated in the TCGA datasets. TCGA-
COAD miRNA data and clinical data (level 3) of the cor-
responding patients (tumor and/or adjacent normal tissue)
were downloaded from the TCGA Data portal (up to May
20, 2016). The expression analyses were carried out using
BRB-ArrayTools (version 4.5, National Cancer Institute,
Bethesda, MD, USA) [24].
Target prediction and functional analysis of miRNA
The presumed targets of integrated-signature miRNAs, es-
pecially the most significant has-miR-195, were identified
by four different target prediction algorithms: TargetScan
v7.1 (http://www.targetscan.org/vert_71/), miRDB (http://
www.mirdb.org/miRDB/), DIANA-TarBase v7.0 (http://dia-
na.imis.athena-innovation.gr/DianaTools/index.php?r=tar-
base/index/), and PicTar (http://pictar.mdc-berlin.de/cgi-
bin/PicTar_vertebrate.cgi). Unique genes with target sites in
3′UTR were incorporated. To assess the prospective func-
tions of the most significant has-miR-195, we discharged
the Kyoto Encyclopedia of Genes and Genomes (KEGG)
using the Database for Annotation, Visualization and Inte-
grated Discovery (DAVID) [25]. The P value that narrated
KEGG pathway enrich the target gene less than 0.05 was
defined as the cutoff criterion.
Tissue collection
Sixty human CRC tissues and PANT (distance to cancer
> 5 cm) were acquired from patients who had been diag-
nosed with primary CRC by pathological assessment of
tissues and undergone surgeries with complete prognostic
information at the Zhongnan Hospital of Wuhan Univer-
sity between January 2011 and December 2015. No local
or systemic neoadjuvant radiotherapy, or/and chemother-
apy and targeted therapy were managed. The study was
approved by the Research Ethics Committee of Wuhan
University (Wuhan, Hubei, PR China). Informed consents
were obtained from all participating patients.
Cell culture and transfection of miR-195 mimic, inhibitor,
and siRNA of target gene
Human colon cancer cell lines DLD1 and HCT116, and
normal intestinal epithelium cell line NCM460 were
purchased from the Cell Bank of Wuhan University. Cells
were cultured in DMEM medium (Gibco, USA) contain-
ing 2 mmol/L glutamine, 10% heat-inactivated (56 °C,
30 min) fetal calf serum, streptomycin (100 U/mL) and
penicillin (100 U/mL), and maintained in a humidified at-
mosphere of 5% CO2 at 37 °C. Hsa-miR-195 mimic and
mimic negative control (NC), hsa-miR-195 inhibitor, and
inhibitor negative control (NC) were purchased from
RiboBio Co., Ltd. (Guangzhou, China). Cells were cultured
in complete medium at least 24 h before transfection.
Cells were washed by phosphate-buffered saline (PBS,
pH 7.4) before transient transfection with 50 nM miR-195-
5p mimic or miR mimic NC, 100 nM miR-195-5p inhibitor
or miR inhibitor NC. Three siRNA duplexes targeting
human YAP1 (GenBank accession no. NM_001130145.2)
were synthesized by RiboBio Company (Guangzhou,
China). Transfections were performed by Lipofectamine
2000 (Invitrogen, USA) according to the manufacturer’s
protocol with RNA oligonucleotides at a final concentration
of 50 nM.
Total RNA extraction and quantitative reverse
transcription polymerase chain reaction (qRT-PCR)
Total RNA was extracted using a Trizol reagent (Invitro-
gen). For the qRT-PCR detection of mature miR-195-5p ex-
pression, we purchased the Bulge-Loop™ miRNA qRT-PCR
Primer Set and Control Primer Set (RiboBio, Guangzhou,
China). RNA (2 μg) was converted into cDNA using the
RevertAid First Strand cDNA Synthesis Kit (Thermo).
QRT-PCR was accomplished using the FastStart Universal
SYBR Green Master (Rox) (Roche) in the ABI PRISM® 7300
real-time PCR system (Applied Biosystems, Foster City,
CA, USA). GADPH and U6 were used as endogenous con-
trols. We used melting curves to monitor non-specific am-
plifications. Relative expression level was computed using
2-ΔΔCt method. The primer sequences used are listed in
Supplemental Experimental Procedures.
Tumor formation in BALB/c nude mice and
immunohistochemistry
BALB/c athymic nude mice (female, 4 – 6 weeks old and
16 – 20 g) were purchased from Hubei Research Center
of Laboratory Animals (Wuhan, China). All animal experi-
ments were carried out in accordance with the Guide for
the Care and Use of Laboratory Animals of Wuhan
University. To establish the CRC cancer xenograft model,
5 × 106 DLD1 cells were suspended in 150 μL PBS and in-
oculated subcutaneously into the flanks of the nude mice.
After 8 days, the transplanted nude mice were randomly
divided into two groups (n = 6 each). MiR-195-5p agomir
or miR agomir NC (RiboBio Co., Ltd, Guangzhou, China)
was directly injected into the implanted tumor at the dose
of 2 nmol/30μL PBS per mouse every 4 days for seven
times. Tumor dimension was measured by length (L) and
width (W) with a caliper every 4 days, and the volumes
were calculated using the formula: (L ×W2)/2. Mice were
sacrificed by cervical dislocation after being anaesthetized
with 10% chloral hydrate at day 36, and the tumors were
excised and snap-frozen for protein and RNA extraction.
Immunohistochemistry of the tumor tissues was per-
formed as described previously [26].
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Statistical analysis
The significance of the differences between the groups
was determined with an ANOVA test or Student’s t test,
and P < 0.05 was considered statistically significant. The
results were expressed as the mean ± SD from at least
three independent experiments. Kaplan-Meier method
and Cox's proportional hazards regression model were
used to calculate overall survivals, and the differences
were analyzed by a log-rank test. Receiver operating
characteristic (ROC) curve analysis was performed
using the code of Mihaly (Additional file 2: Supple-
mental R script) by R Software (version 3.2.3; http://
www.r-project.org) [27].
Supplemental experimental procedures include the fol-
lowing information: dual luciferase reporter assays, BrdU
immunofluorescence assay, colony formation assay,
CCK8 assay, wound healing assay in vitro, transwell mi-
gration/invasion assay, transfection reagents, primers,
western blot analysis, and antibody (Additional file 3:
Supplemental Experimental Procedures).
Results
Integrated analysis of seven CRC miRNAs expression
datasets identified 21 significantly deregulated miRNAs in
CRC
We located and manually curated 23 published and
publicly available CRC datasets (see Methods; Add-
itional file 4: Table S2). We identified seven datasets
that met the criteria listed in Methods (387 CRC
samples and 386 PANT samples; Additional file 5:
Table S3). The study selection flow chart for this inte-
grated analysis is shown in Fig. 1a. After merging the
datasets, 32 differential miRNAs were identified.
Twenty-five miRNAs were retained after filtering by
the mean and SD (10%) to filter small expression in-
tensities and small variation genes. We identified 21
miRNAs showing consistent DE patterns using a
moderated t test by adding a fudging parameter, and
Fisher’s method by summarizing -log(P value) across
studies and running 300 permutations to eliminate
significant influence of the large number of samples
[28]. One-sided tests revealed 10 upregulated (highly
expressed) miRNAs in CRC compared with PANT
(Additional file 6: Table S4) and 11 downregulated
(lowly expressed) ones in CRC compared with PANT
(Additional file 7: Table S5). After combining the ef-
fect size, we identified a total of 21 DE miRNAs that
showed similar profiles of DE genes to those using
Fisher’s method of combining P value (P < 1E-19;
Additional file 8: Table S6). As expected, hierarchical
clustering of the seven datasets using the 11 down-
regulated miRNAs could distinguish the CRC from
the PANT samples (Fig. 1b).
Integrated-signature miRNAs showed clinical prognostic
significance in CRC patients
We further validated the 11 DE miRNAs in TCGA-COAD
(268 CRC, 8 adjacent normal tissue; Table 1, Additional file
9: Table S7, Fig. 1c). Only hsa-let-7a, hsa-miR-125b, hsa-
miR-145, and hsa-miR-195 were significantly downregu-
lated in CRC tumors (Fig. 1c), and each of these miRNAs
could provide a high accuracy on CRC tissue classification
as estimated by ROC curve analysis (Fig. 2a; Additional file
10: Figure S1a). We optimized the accuracy by using a
linear regression model built on a panel of the combined
miRNAs (AUC= 1): CRC risk score = 5.091E_miR-125b–
57.423E_miR-145–86.136E_let-7a + 25.798E_miR-195 + 17
12.826, where E_miR-n = Log 2 (expression of microRNA)
(Fig. 2b).
To further investigate whether the deregulated miR-
NAs correlate with the survivals of the CRC patients, we
performed Kaplan-Meier and Cox’s proportional hazards
regression model analysis and found that low miR-195
level was significantly correlated with poor overall sur-
vivals of CRC patients (Fig. 2c, Table 2), suggesting the
prognostic value of miR-195-5p in clinical CRC dia-
gnosis. The downregulation of miR-195 has been co-
nsistently observed in the CRC patients with poor
overall survivals, indicating that miR-195 may be func-
tionally important in CRC pathogenesis. In contrast, low
levels of let-7, miR-125b, or miR-145 in TCGA CRC tis-
sues were correlated with improved overall survivals
(Additional file 10: Figure S1b).
Functional enrichment and target prediction of miR-195
Significantly, in spite of the presence of biological and
technical confounding factors, such as the differences in
sample cohorts, treatments, and microarray technologies,
in all eight independent CRC expression microarrays, our
results indicated the importance of miR-195 expression in
human CRC (Fig. 2d). We conducted target prediction for
validated miR-195 with high-stringency. Target genes were
obtained from both prediction algorithms and experimen-
tally supported databases. The counts of predicted targets,
experimentally validated targets, prediction-based consen-
sus targets, and 71 consensus target genes were summa-
rized (Fig. 2e, Additional file 11: Table S8). In addition,
we performed KEGG pathway analysis to elucidate the
potential biological functions of miR-195 integrated-
signature. Interestingly, the top KEGG pathways
enriched for the miR-195 targets were mainly associ-
ated with cancer-specific pathways (Additional file 12:
Table S9), including the Hippo signaling pathway, pro-
teoglycans in cancer, viral carcinogenesis, pathways in
cancer, and prostate cancer (Fig. 2f ). In previous
analysis, the Hippo signaling pathway was significantly
enriched for the predicted targets of miR-195-5p (P =
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Fig. 1 (See legend on next page.)
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6.47E-05) (Additional file 13: Figure S2). Taken together,
these results indicate that deregulated miR-195 expression
plays a critical role in human CRC.
Downregulation of miR-195-5p is concomitant with up-
regulation of YAP1 in primary human CRC
As miR-195 showed a consistent pattern of downexpres-
sion in human CRC, we wondered about the expression
pattern of miR-195-5p in the colon cancer cell lines.
Similarly, we found a lower expression of miR-195-5p in
DLD1 and HCT116 cell lines, compared with the nor-
mal intestinal epithelium cell line NCM460 (Fig. 3a).
Next, we measured the mature miR-195-5p level in an
independent validation sample cohort (n = 60) by qRT-
PCR (normalized with U6). The results showed that miR-
195-5p expression in the tumors was significantly (P < 0.05)
reduced in the tumors relative to PANT (Fig. 3b). Addition-
ally, Kaplan–Meier and Cox’s proportional hazards regres-
sion model survival analysis revealed that patients with low
expression levels of miR-195-5p had shorter overall survival
(Fig. 3c, Table 2). Thus, given the results of the integrated
analysis and the in vitro experiments, we hypothesize that
the decreased expression of miR-195-5p may promote CRC
progression and development.
Since the Hippo pathway emerged in our previous
KEGG analysis for the miR-195 targets, it is conceivable
that miR-195 may directly regulate this pathway during
CRC tumorigenesis. Meanwhile, the protein-protein inter-
action network (PPI) suggested that YAP1 is the hub gene
of the miR-195 targets (Additional file 14: Figure S3).
YAP1 is the pivot in the Hippo signaling pathway leading
to potent oncogenicity, and can promote cell growth, mi-
gration, invasion, and EMT in many tumors including
CRC. Therefore, we also examined YAP1 expression in
this sample cohort comprising the 60 human CRC and
PANT. Both qRT-PCR and western blot results showed
that YAP1 was significantly upregulated in CRC compared
with PANT (Fig. 3d). Significantly, the miR-195-5p level
was inversely correlated with the YAP1 level in the tumors
as calculated by Pearson’s correlation (R2 = 0.531, P =
4.02E − 11) (Fig. 3e), suggesting that miR-195-5p may
downregulate YAP1 in CRC (Fig. 3e). Of note, Kaplan–
Meier and Cox’s proportional hazards regression model
also revealed that patients with high levels of YAP1 had
shorter overall survivals (Fig. 3f, Table 2).
(See figure on previous page.)
Fig. 1 Eleven downregulated genes were identified by integrated analysis of CRC miRNA expression datasets. a The flowchart of the integrated
analysis and functional validation. In silico bioinformatics data analysis pipeline consists of curation of seven publically available datasets, data
preprocessing, metaDE and integrated analysis, TCGA dataset validation, validation for diagnostic/prognostic values, KEGG pathway and target gene
validation, and in vitro and in vivo functional validation. b Clustering of the 11 genes in CRC vs. PANT across each independent dataset. Each column
represents a sample and each row represents the expression level of a given miRNA. The color scale represents the raw Z score ranging from blue (low
expression) to red (high expression). Dendrograms by each heatmap correspond to the hierarchical clustering by expression of the 11 miRNAs. c
Expression of the downregulated miRNAs is plotted for tumor and normal tissues (TCGA dataset). Expression values of miRNAs are log2-transformed
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MiR-195-5p inhibits proliferation and colony formation of
colon cancer cells
We next examined the pathophysiological significance of
miR-195-5p downregulation in CRC and its underlying
regulatory mechanisms. We transfected DLD1 and
HCT116 cells with miR-195-5p mimic or miR mimic NC,
and miR-195-5p inhibitor or miR-195-5p inhibitor NC,
separately. We first examined the effect of miR-195-5p on
proliferation of DLD1 and HCT116 cells. BrdU incorpor-
ation assay revealed that miR-195-5p inhibited DNA syn-
thesis in DLD1 and HCT116 cells (Fig. 4a–b). In contrast,
miR-195-5p inhibitor treatment could lift this inhibition
(Fig. 4a–b). In addition, clonogenic assay showed that
miR-195-5p mimic treatment decreased the clonogenic
survivals of DLD1 and HCT116 cells compared with blank
controls, while miR-195-5p inhibitor-treated DLD1 and
HCT116 cells showed a reversed phenotype (Fig. 4c–d),
suggesting miR-195-5p negatively regulates cancer cell
proliferation. Supporting this notion, a colorimetric based
cellular proliferation assay (i.e., CCK8 assay) showed con-
sistent phenotypes when treating with miR-195-5p mimic
or its inhibitor (Fig. 4e–f ).
MiR-195-5p inhibits migration and invasion of colon
cancer cells
Invasion and migration through the basement membrane
are characteristics of metastatic cancer cells. We assessed
the role of miR-195-5p on the migration and invasion of
DLD1 and HCT116 cells. In the scratch wound healing
assay, cell motility of cells was monitored at different time
points after generation of the wound. The miR-195-5p-ex-
pressing cells migrated toward the wound at a much
slower rate than the control or the cells treated by miR-
195 inhibitors (Fig. 5a–b). In the transwell invasion and
migration assay, we found that invasion and migration of
the miR-195-5p-expressing cells was reduced, and this ef-
fect could be reversed by the miR-195-5p inhibitor
(Fig. 5c–f ). These results, taken together, clearly demon-
strate that miR-195-5p negatively regulates invasion and
migration of colon cancer cells.
MiR-195-5p targets human YAP1 and inhibits YAP1 in
colon cancer cells
To test if YAP1 expression is regulated by miR-195-5p,
we cloned the YAP1 3′-UTR into a luciferase reporter
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Fig. 2 The four validated downregulated miRNAs may serve as significant prognostic markers in CRC classification. a An ROC curve built on a
univariate classification model based on miR-195 expression across independent TCGA dataset for predicting CRC. b Performance of the four miR-
NAs on CRC tissue classification. CRC risk score was built using a linear regression model by R software. c Kaplan–Meier plots for overall survival
for a discriminatory median miR-195 expression, from TCGA sequencing data to assess prognostic accuracy. P values were calculated using the
log-rank test. d Forest plots summarizing the downregulation of hsa-miR-195 from eight datasets in the integrated analysis. Each row represents a
study with standardized mean difference between CRC and normal tissues (black dot) and the confidence interval of 95% (dark line). The size of
the gray box is proportional to the relative effect size of each dataset. The dotted vertical line at 0 represents the null hypothesis. The diamonds
represent overall, combined mean difference for miR-195. Thus, negative values indicate downregulation of miR-195 in CRC. e Venn diagrams of
putative miR-195 targets predicted by TargetScan (v7.1), miRDB, PicTar, and DIANA-TarBase (v7.0). f Top ten KEGG pathways that are enriched for
the miR-195 targets are mainly cancer-specific pathways
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plasmid (Fig. 6a) and we quantified expression of the ad-
jacent hRluc coding region. For this purpose, we
searched different databases for the potential targets of
miR-195-5p that exhibited oncogenic properties. YAP1,
which harbors two conserved miR-195-5p cognate sites,
namely, 162-168 and 1857–1862 of YAP1 3′-UTR
(Fig. 6b), is a predicted target of miR-195-5p. The lucif-
erase reporter plasmid pmiR-RB-REPORTTM-YAP1-3′-
UTR or mutant reporter plasmid carrying point
mutations in the putative miR-195-5p binding sites was
co-transfected with miR-195-5p mimics or miR mimic
NC and inhibitors, separately. The results showed that
miR-195-5p suppressed luciferase activity whereas miR-
195-5p inhibitor could promote luciferase activity for
the reporter plasmid carrying wild-type YAP1 3′-UTR
(Fig. 6c, P < 0.05), but no significant effects were observed
for the reporter plasmid carrying mutant YAP1 3′-UTR
(i.e., pmiR-RB-REPORTTM-mut-YAP1-3′-UTR). These re-
sults suggest that miR-195-5p binds directly to the
predicted binding site(s) in the YAP1 3′-UTR and nega-
tively regulates YAP1 expression.
To confirm the direct regulation of miR-195-5p on
YAP1 expression, we transfected DLD1 and HCT116 cells
with miR-195-5p mimic, miR mimic NC, miR-195-5p in-
hibitor, and miR-195-5p inhibitor NC. Both qRT-PCR and
western blotting revealed that the YAP1 level was reduced
in miR-195-5p-expressing cells, while its level was re-
stored in miR-195-5p inhibitor-treated cells (Fig. 6d–f ).
The conversion from epithelial cells to mesenchymal cells,
characterized by spindle-type cell morphology, was ob-
served in HCT116 cells treated with miR-195-5p inhibitor
(Additional file 15: Figure S4). So far, the results suggest
that miR-195-5p negatively regulates YAP1 levels in CRC
cells. Additionally, expressions of TAZ, Vimentin, ZEB2,
and SMAD3 protein were also negatively regulated by
miR-195-5p, while E-cadherin was positively regulated by
miR-195-5p, suggesting the negative regulations of miR-
195-5p on the Hippo pathway and EMT in CRC cells.
Table 2 Univariate and multivariate analyses of clinicopathological characteristics, miR-195-5p, and YAP1 with overall survival in
TCGA COAD cohort and independent validation cohort
Univariate analysisa Multivariate analysisb
HR (95% Cl) P value HR (95% CI) P value
TCGA COAD testing set (n = 240)
Gender(male vs. female) 1.938(1.065–3.526) 0.030 2.512(1.321–4.775) 0.005
Age, years (≥median vs. < median) 1.591(0.843–3.003) 0.152
Nodes count (12 or more vs. fewer than 12) 0.726(0.402–1.309) 0.287
Lymphatic invasion (present vs. absent) 2.171(1.238–3.809) 0.007 1.453(0.572–3.694) 0.432
Pathologic M stage (present vs. absent) 3.060(1.652–5.667) 0.001 1.969(0.988–3.924) 0.034
TNM stage (III and IV vs. I and II) 2.099(1.185–3.717) 0.011 1.206(0.573–2.536) 0.622
Vascular invasion (present vs. absent) 2.400(1.318–4.372) 0.004 1.660(0.719–3.830) 0.235
Preoperative CEA level
(≥5 μg/mL vs. <5 μg/mL)
0.982(0.542–1.780) 0.953
Hsa-miR-195 (≥median vs. < median) 0.488(0.262–0.910) 0.023 0.419(0.214–0.819) 0.011
YAP1 (≥median vs. < median) 2.022(1.120–3.652) 0.019 1.379(0.714–2.664) 0.339
Independent validation cohort (n = 60)
Gender(male vs. female) 0.879(0.494–1.564) 0.661
Age, years (≥median vs. < median) 0.823(0.458–1.478) 0.514
Nodes count (12 or more vs. fewer than 12) 1.323(0.724–2.418) 0.363
Lymphatic invasion (present vs. absent) 1.542(0.852–2.790) 0.153
Pathologic M stage (present vs. absent) 16.910(5.793–49.361) <0.001 4.140(2.825–5.442) 0.001
TNM stage (III and IV vs. I and II) 1.542(0.852–2.789) 0.153
Vascular invasion (present vs. absent) 1.060(0.541–2.075) 0.866
Preoperative CEA level
(≥5 μg/mL vs. <5 μg/mL)
0.893(0.506-1.573) 0.695
Hsa-miR-195 (≥median vs. < median) 0.526(0.294–0.941) 0.031 0.704(0.344–0.875) 0.044
YAP1 (≥median vs. < median) 1.969(1.092–3.547) 0.024 1.476(0.623–3.497) 0.377
aThe data were subjected to Cox’s proportional hazards regression model. Bold italics indicate statistically significant values (P < 0.05)
bMultivariate analysis used stepwise addition and removal of clinical covariates found to be associated with survival in univariate models (P < 0.05) and final models
include only those covariates that were significantly associated with survival (Wald statistic, P < 0.05). Bold italics indicate statistically significant values (P < 0.05)
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Silence of YAP1 expression inhibits colon cancer cell
growth, clone formation, invasion, migration, and rescue
assay
We next evaluated the potential tumorigenicity of YAP1
in CRC. Silence of YAP1 expression by siRNA signifi-
cantly inhibited the expression of YAP (Additional file
16: Figure S5). Moreover, loss of YAP1 expression also
contributed to inhibition of colon cancer cell (DLD1 and
HCT116 cells) growth (Additional file 16: Figure S5a),
clone formation (Additional file 16: Figure S5b–c), inva-
sion, and migration (Additional file 16: Figure S5d–e).
These results further verified the powerful tumo-
rigenicity of YAP1 in CRC. These results indicated that
the anti-cancer and reverse EMT efficacy of miR-195-5p
is partly attributed to its inhibitory role on YAP, which
was confirmed by qRT-PCR and western blot of YAP1
(Additional file 16: Figure S5f-g) in DLD1 cells.
MiR-195-5p suppresses tumor growth in vivo
To confirm the tumor suppressor role of miR-195-5p in
vivo, we established a BALB/c nude mouse xenograft
model using DLD1 cells. Starting day 8 post-implantation,
we injected miR-195-5p agomir or miR agomir NC intra-
tumorally every 4 days for 7 treatments. We evaluated in
vivo tumor growth by measuring the tumor volumes and
weights. Both the volumes and weights of the tumors
treated with miR-195-5p agomir were significantly re-
duced relative to those treated with miR agomir NC
(Fig. 7a–d). Therefore, miR-195-5p significantly inhibits
the tumorigenicity of DLD1 cells in vivo. Additionally,
consistent with the proposed regulations of miR-195-5p
on the Hippo pathway and EMT, expression patterns of
YAP, Ki67, Vimentin, ZEB2, and E-cadherin in miR-195-
5p-agomir-treated tumors were similar to the in vitro re-
sults, substantiating the tumor suppressor function of
miR-195-5p in CRC tumorigenesis (Fig. 7e–g).
Discussion
Integrated analysis, a conscientious approach to unify
cross-platform standardization of gene profiling and over-
look the unavailability of raw data, has been used to identify
differentially expressed genes at the mRNA and miRNA
Fig. 3 Expressions of miR-195-5p and YAP1 are inversely correlated in primary CRC tumors. a Expression of miR-195-5p in two colon cancer cell
lines, DLD1 and HCT116, and the normal NCM460 cells. Assays were performed in triplicates. b MiR-195-5p is significantly decreased in primary
human CRC tissues compared with PANT. Mean ± SD is shown. Statistical analysis was conducted using Student's t test. c Kaplan–Meier curves of
the overall survivals (OS) reveal that downregulated miR-195-5p is associated with poor prognosis in CRC patients. P value was obtained by a log-
rank test. d YAP1 mRNA and protein levels are shown for the CRC tissues and PANT. e Scatter plots showing the inverse association between miR-
195-5p and YAP1 mRNA levels. f Kaplan–Meier analysis of OS based on YAP1 mRNA levels in 60 cases of CRC patients
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level in CRC [29, 30]. Chen et al. overcame the drawback of
lack of conformity among miRNA expression profiling
studies in CRC by means of directly combining the ranks of
prioritized miRNA lists but not re-analyzing the raw miR-
NAs profiles [31]. However, they failed to consider the
effects of small sample size and heterogeneity of the indi-
vidual studies because they included 17 studies whose sam-
ple size was under 30 pairs in total 24 studies. Conversely,
our integrated analysis of the raw data of the seven studies
whose sample size is over 30 pairs reliably reveals the differ-
ential miRNAs across various platforms.
Our current study supports the validity and effectiveness
of this integrated strategy. Firstly, reduced expression of
miR-195-5p in primary CRC was revealed independently
by both integrated analysis and TCGA-COAD validation
analysis, suggesting miR-195-5p can be an effective diag-
nostic and prognostic marker in the clinical setting. Sec-
ondly, ectopic expression of miR-195-5p in colon cancer
cell lines considerably decreased cell growth, migration,
and invasion. Thirdly, miR-195-5p can directly regulate
expression of YAP1 by targeting its 3′-UTR. It can inhibit
expression of YAP1, TAZ, Vimentin, ZEB2, and SMAD3,
Fig. 4 Ectopic expression of miR-195-5p inhibits proliferation and colony formation of DLD1 and HCT116 cells. Representative photomicrographs
(a) and quantifications (b) of BrdU staining in DLD1 and HCT116 cells after transfection with miR-195-5p mimic, miR-195-5p mimic NC, miR-195-5p
inhibitor, or miR-195-5p inhibitor NC for 48 h. Bar = 100 μm. Representative photomicrographs (c) and quantifications (d) of the colony formation assay
after transfection with miR-195-5p mimic, miR-195-5p mimic NC, miR-195-5p inhibitor, or miR-195-5p inhibitor NC for 8 days. CCK8 cell proliferation
assays in DLD1 (e) and HCT116 (f) cells transfected with indicated miRNAs. Assays were performed in triplicates. Mean ± SD is shown. Statistical analysis
was conducted using one-way ANOVA. *P < 0.05. **P < 0.01. ***P < 0.001
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and promote E-cadherin expression in colon cancer cells.
Finally, miR-195-5p suppressed tumor growth in vivo.
The goals of the current study were to identify the can-
didate driver miRNAs in CRC through meta-analysis of
multiple datasets of miRNA expression arrays and to val-
idate their biological functions and significance for clinical
diagnosis and prognostic prediction. The integrated ana-
lysis method described here was designed to exclude the
low precision studies, account for biases inherent in single
studies, and nominate prevalently dysregulated miRNAs.
Taking into account these considerations, we have in-
cluded seven miRNAs expression data from seven differ-
ent platforms in CRC using the MetaDE method, which
provided options for gene merging, matching across stud-
ies, and gene filtering [22]. We screened 10 upregulated
and 11 downregulated miRNAs in CRC samples using
moderated t test and Fisher’s method by summarizing
-log(P value). In addition, we validated and obtained 4
downregulated miRNAs (i.e., hsa-let-7a, hsa-miR-125b,
hsa-miR-145, and hsa-miR-195) from over 250 tumors
from the TCGA-COAD database which granted us the
opportunity to systematically analyze the potential mo-
lecular mechanisms associated with the pathophysiology
of CRC. These four miRNAs seem to have a context-
specific value as a diagnostic marker of CRC. For hsa-let-
7a, hsa-miR-125b, and hsa-miR-145, previous reports have
shown their downregulation was correlated with the anti-
tumor effect in CRC [31, 32]. In this study, we found that
hsa-let-7a, hsa-miR-125b, and hsa-miR-145 were down-
regulated in CRC and correlated with improved survivals
of CRC patients. Only the low level of miR-195 in tumors
was substantially correlated with reduced overall survivals
of CRC patients, suggesting miR-195 may negatively regu-
late CRC progression.
MiR-195 as a tumor suppressor has been reported in
various types of cancer. It is a member of paralogous,
evolutionarily conserved miRNAs termed the miR-15/
107 family that has been suggested to have considerable
potential in prognostic prediction [33–38]. Soon et al.
found aberrant expression of miR-195 could indicate a
Fig. 5 Ectopic expression of miR-195-5p in DLD1 and HCT116 cells reduces cell migration and invasion. a–b Representative photomicrographs of
wound-healing assay in DLD1 and HCT116 cells after transfected miRNAs. Bar = 100 μm. c Transwell invasion assays of DLD1 and HCT116 cells carrying
different miRNAs. Bar = 100 μm. d Total number of cells in five fields was counted manually. e Transwell migration assays of DLD1 and HCT116 cells
carrying different miRNAs. Bar = 100 μm. f Total number of cells in five fields was counted manually. Mean ± SD are shown. Statistical analysis was
conducted using one-way ANOVA. *P < 0.05. **P < 0.01. ***P < 0.001
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poorer prognosis in adrenocortical carcinoma [39]. Li et
al. found that extracellular vesicles delivering miR-195 to
intrahepatic cholangiocarcinoma could decrease the
tumor size and improve survivals in a rat model [40].
Luo et al. found miR-195 might tender a novel tactic for
the diagnosis and treatment of breast cancer patients
[41]. In our study, we confirmed that miR-195 was
downregulated in CRC tissues, which was significantly
correlated with poor survivals of CRC patients. We in-
vestigated the mechanism of miR-195-5p-mediated
regulations on colon cancer cells and found that over-
expression of miR-195-5p markedly inhibited cellular
proliferation and invasion of CRC cells. Supported by
miRNA target analysis and luciferase reporter assays, we
propose that miR-195-5p targets the 3′-UTR of YAP1
mRNA and inhibits YAP expression, leading to prolifera-
tive inhibition in CRC cells. Furthermore, the present
study also shed light on the potential role of miR-195-5p
in CRC metastasis, where ectopic expression of miR-
195-5p could reduce cell migration and invasion and
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Fig. 6 miR-195-5p targets the 3′-UTR of YAP1 mRNA. a A schematic representation of the pmiR-RB-REPORTTM dual luciferase reporter vector. b
The 3′-UTR of YAP1 mRNA harbors two miR-195-5p cognate sites. c Relative luciferase activity of reporter plasmids carrying wild-type or mutant
YAP1 3′-UTR in DLD1 and HCT116 cells co-transfected with negative control (NC) or miR-195-5p mimic or miR-195-5p inhibitor. Expression of YAP1
mRNA in DLD1 (d) and HCT116 cells (e) transfected with the indicated miRNAs. f Western blots of YAP, TAZ, Vimentin, ZEB2, SMAD3, and E-
cadherin in DLD1 and HCT116 cells transfected with different miRNAs. Assays were performed in triplicates. Mean ± SD is shown. Statistical ana-
lysis was conducted using Student’s t test. *P < 0.05. **P < 0.01
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promote expression of the EMT marker, E-cadherin. To
our knowledge, this is the first meta-analysis that reveals
the detailed mechanism where loss of miR-195-5p leads
to malignant progression of CRC via unleashed expres-
sion of YAP1.
It is well known that Hippo signaling controls cell
growth and differentiation [42]. In several tumors,
aberrant activation of the Hippo/YAP signaling pathway
represents one of the most important mechanisms ac-
counting for oncogenic progression and invasiveness,
and has been recognized as a prognostic factor of poor
outcome [11, 43–52]. Major signal transducers of the
Hippo pathway were proposed as prognostic factors in
colorectal cancer [53, 54]. We also identified the Hippo
signaling pathway as being enriched in the prediction
analysis of the miR-195-5p targets. Experimentally, we
verified that the Hippo pathway core effector YAP1
mRNA 3′-UTR had two conserved miR-195-5p cognate
sites. Interestingly, we also found that loss of miR-
195-5p accelerated YAP expression and promoted nu-
clear accumulation of YAP and EMT in vitro [19, 55,
56]. Hence, major players in this pathway may be
tightly regulated by miR-195-5p in the colorectum,
and miR-195-5p restoration could target YAP/TAZ/
EMT pathway to suppress CRC progression. Further-
more, it is likely that other molecules or signaling
pathways will be discovered that are also targeted by
miR-195-5p in CRC. Future work will focus on re-
vealing additional functions of miR-195-5p in CRC
carcinogenesis and progression.
Fig. 7 Ectopic expression of miR-195-5p suppresses tumor growth in vivo. The volumes (a) and weights (b) of the tumors grown in the xenograft
mouse model. Data are presented as mean ± SD (n = 6); *P < 0.05. Photographs of the mice (c) and dissected tumors (d) that were treated with or
without Agomir-195-5p. e Expression of YAP1 mRNA in DLD1 tumors. f Western blots of YAP, Ki67, E-cadherin, vimentin, and ZEB2 in the tumors.
β-actin was used as a loading control. g Immunohistochemistry of tumor tissues treated with or without miR-195-5p. Assays were performed in
triplicates. Mean ± SD is shown. Statistical analysis was conducted using Student’s t test.
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Conclusions
In summary, we have performed integrated analysis of miR-
Nomes of human normal colorectum and CRC tissues,
which provided us rich resources for exploring the roles of
miRNAs in CRC. Four downregulated miRNAs (hsa-let-7a,
hsa-miR-125b, hsa-miR-145, and hsa-miR-195) can be po-
tentially useful diagnostic markers in the clinic. Among
them, only miR-195 is inversely correlated with overall
survival in CRC patients. We have demonstrated that miR-
195-5p is dramatically downregulated in human CRC tis-
sues compared with normal colorectal tissues. Moreover,
upregulation of miR-195-5p suppresses proliferation, mi-
gration, invasion, and EMT of colon cancer cells through
targeting the YAP1 mRNA 3′-UTR. Collectively, miR-195-
5p suppresses tumor cell growth in vitro and tumorigen-
icity in vivo. Our study may serve as rational for targeting
the miR-195-5p/YAP interaction in a novel therapeutic ap-
plication to medicate CRC patients.
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